Thursday, February 05, 2015 1:27:21 PM
MARLBOROUGH, Mass., Feb. 5, 2015 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapies addressing high-unmet medical needs, today announced the closing of its previously disclosed exclusive global license agreement for the therapeutic use of Samcyprone™ with Hapten Pharmaceuticals, LLC.
Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
Under the terms of the license agreement, Hapten received a one-time upfront cash payment of $100,000 and 200,000 shares of RXi common stock. Hapten will also be entitled to receive future milestone payments tied to the achievement of certain clinical and commercial objectives, such as the enrollment of the first patient in a Phase 3 clinical trial and regulatory approval, and escalating royalties based on product sales.
About Samcyprone™
Samcyprone™, a proprietary immunomodulating topical gel containing the active agent diphenylcyclopropenone (DPCP), is currently in Phase 2a clinical trials for the treatment of alopecia areata, warts and cutaneous metastases of malignant melanoma. The proprietary gel formulation of DPCP, developed by Hapten Pharmaceuticals, LLC, should provide an improvement in the overall safety and tolerability profile compared to treatment with DPCP as currently used. Typically, patients treated with DPCP are initially sensitized with a single high concentration of drug and subsequently treated with low non-irritant concentrations. Use of high concentrations of DPCP during the sensitization dose results in hyper-sensitizing the patient to subsequent challenge doses. In contrast, the use of Samcyprone™ results in sensitization using a much lower concentration of DPCP, avoiding hyper-sensitization to challenge doses, which should result in an improved safety and tolerability profile while maintaining the known efficacy of DPCP.
Additional information on Samcyprone™ is available and may be found on the "Technology" section of the Company's website, www.rxipharma.com.
About Hapten Pharmaceuticals, LLC
Hapten Pharmaceuticals, LLC is an early stage dermatology product development company based in New York, NY. Hapten's Samcyprone™ is a topical immunomodulator that incorporates DPCP in a proprietary gel formulation.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company focused on discovering and developing innovative therapeutics, primarily in the area of dermatology and ophthalmology, addressing high-unmet medical needs. Our discovery and clinical development programs are based on siRNA technology as well as immunotherapy agents. These compounds include, but are not limited to, our proprietary, self-delivering RNAi (sd-rxRNA®) compounds for the treatment of dermal and retinal scarring. It also includes an immunomodulator, Samcyprone™, a proprietary gel formulation of diphenylcyclopropenone (DPCP), for the treatment of such disorders as alopecia areata, warts, and cutaneous metastases of melanoma.
RXi's robust pipeline, coupled with an extensive patent portfolio, provides for product and business development opportunities across a broad spectrum. We are committed to being a partner of choice for academia, small companies, and large multinationals. We welcome ideas and proposals for strategic alliances, including in- and out-licensing opportunities, to advance and further develop strategic areas of interest.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations and planned and future development of RXi Pharmaceuticals Corporation's products, technologies and partnerships. Forward-looking statements about expectations and development plans of RXi's products and partnerships involve significant risks and uncertainties such as: the risk that we may not be able to successfully develop and commercialize the Samcyprone™ product candidates, or that development of the Samcyprone™ product candidates may be delayed or not proceed as planned, risks related to the development and commercialization of products by our competitors, the risk related to our ability to control the timing and terms of collaborations with third parties and the possibility that other companies or organizations may assert patent rights preventing us from developing our products. Actual results may differ from those contemplated by these forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com
SOURCE RXi Pharmaceuticals Corporation
RELATED LINKS
http://www.rxipharma.com
More by this Source
RXi Pharmaceuticals Strengthens Intellectual Property Portfolio for Ocular Indications
Feb 03, 2015, 07:02 ET
RXi Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference
Feb 02, 2015, 07:02 ET
RXi Pharmaceuticals to Present at the 7th Annual Biotech Showcase™
Jan 05, 2015, 07:02 ET
View all news by RXi Pharmaceuticals Corporation
Recent PHIO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/13/2024 07:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/13/2024 06:59:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 08:11:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/15/2024 08:14:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 09:00:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:45:46 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 01:05:02 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/05/2024 12:00:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 12:00:10 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/26/2024 08:30:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/28/2024 09:00:13 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/20/2024 09:03:23 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 05/20/2024 08:59:26 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/17/2024 08:45:23 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/17/2024 01:04:34 PM
- Phio Pharmaceuticals Secures New Investor • GlobeNewswire Inc. • 05/17/2024 01:00:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 01:00:13 PM
- Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID) • GlobeNewswire Inc. • 05/16/2024 12:00:00 PM
- Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study • GlobeNewswire Inc. • 05/15/2024 05:00:00 PM
- Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 09:25:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 09:23:21 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM